The TNF signaling pathway, (Tumor Necrosis Factor pathway), plays a central role in mediating inflammation and immune responses, influencing processes from cell survival and proliferation to apoptosis. TNF signaling is pivotal in responding to infections, injuries, and immune challenges, often becoming a critical factor in autoimmune and inflammatory diseases.
AnyGenes offers specialized qPCR array products designed to assist researchers in examining gene expression changes within the TNF signaling pathway. These arrays are invaluable for profiling gene expression linked to inflammation, apoptosis, and immune responses, providing insights that aid in understanding the pathway’s role in disease progression and therapeutic intervention.
Overview of the TNFR1 and TNFR2 signaling pathway. All TNFR1-exclusive signaling mediators are marked red, whereas all TNFR2-exclusive signaling components are shown in blue. All mediators used by both pathways are labeled orange.
In health, the TNF signaling pathway plays a vital role in protecting the body against infections and injuries. It helps to regulate the immune response, promote inflammation to fight off pathogens, and remove damaged cells through apoptosis. However, dysregulation of TNF signaling can lead to pathological conditions.
Chronic activation of the TNF signaling pathway is associated with various inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Additionally, excessive TNF signaling has been implicated in cancer, as it can promote tumor growth and survival. Understanding these mechanisms is crucial for developing therapies aimed at modulating TNF activity in disease.
Given its central role in inflammation and immune response, the TNF signaling pathway is a prime target for therapeutic intervention. Anti-TNF drugs, such as infliximab and adalimumab, are widely used in treating autoimmune diseases like rheumatoid arthritis and Crohn's disease. These drugs work by neutralizing TNF-alpha, thereby reducing inflammation and tissue damage.
Combination therapies that utilize sTNF/TNFR1 antagonists in conjunction with TNFR2 agonists could help rebalance pathologically deregulated TNF signaling, promoting tissue repair. This approach represents a promising and innovative therapeutic strategy for addressing a variety of inflammatory and degenerative diseases.
Customize your own signaling pathways (SignArrays®) with the factors of your choice!
Simply download and complete our Personalized SignArrays® information file
and send it at
contact@anygenes.com
to get started on your project.